Soluble guanylate cyclase induces cranial vasodilation and headache in adults: a randomized trial
Abstract
The role of cranial vasodilation in headache pathogenesis sparks ongoing debate. Soluble guanylate cyclase is an enzyme that catalyses the conversion of guanosine triphosphate to cyclic guanosine monophosphate, leading to relaxation of vascular smooth muscle cells. Activation of this pathway might contribute to headache pathogenesis. We evaluated whether oral ingestion of riociguat, a stimulator of soluble guanylate cyclase, could elicit cranial vasodilation and headache in healthy adults. In this randomized, double-blind, placebo-controlled, two-way crossover study, we enrolled 12 healthy adults (nine females, three males; mean age 27.3 (SD 7.8) years). The participants attended two experimental sessions at a single site in Denmark (Danish Headache Center, Rigshospitalet, Denmark), receiving either a single oral dose riociguat 2.5 mg or placebo. The baseline measurements included the diameter of the superficial temporal artery and the blood flow velocity of the middle cerebral artery. These measurements were repeated over a 240-minute period after ingestion. The participants recorded headache occurrence and associated features in a diary for 12 h post-ingestion. For primary outcome (n = 12), results revealed no significant change in the diameter of the superficial temporal artery from baseline to 90 min post-ingestion between riociguat and placebo (P = 0.54). However, significant increases in the diameter were observed at 120 min (P = 0.02) and 240 min (P P P = 0.02). In…
How strong is the evidence?
Evidence Hub reads this as a randomized trial, done in people. Its evidence level is 3 of 5 (Moderate · trial / cohort / secondary analysis). Trials without a large randomized design, cohorts and secondary analyses give moderate evidence. Reported size: 12 participants or records.
Read the paper
Related studies
- Drug repositioning: a brief overview
- Cyclic nucleotide phosphodiesterases in Drosophila melanogaster
- Time-resolved in silico modeling of fine-tuned cAMP signaling in platelets: feedback loops, titrated phosphorylations and pharmacological modulation
- Current View on Green Tea Catechins Formulations, Their Interactions with Selected Drugs, and Prospective Applications for Various Health Conditions
- In silico Structure-based Identification of Novel Acetylcholinesterase Inhibitors Against Alzheimer’s Disease
- Development and In Vitro Evaluation of Controlled Release Viagra® Containing Poloxamer-188 Using Gastroplus™ PBPK Modeling Software for In Vivo Predictions and Pharmacokinetic Assessments
Go deeper in Evidence Hub
Evidence Hub adds a study data sheet (design, sample size, evidence level, key numbers), an AI summary and a chat grounded in the paper's text.